Skip to content
Regenerus Laboratories just secured £8 million to transform diagnostic testing with faster, smarter, and more accessible health insights worldwide. Discover how their cutting-edge platform is set to revolutionize personalized care and early detection across the UK and beyond!
Imagine a future where diagnostic testing is not only faster and more accurate but also seamlessly accessible to healthcare practitioners worldwide. This vision is rapidly materialising thanks to Regenerus Laboratories, a pioneering UK-based diagnostic health testing company. Recently, Regenerus secured a substantial £8 million investment, combining a £5 million equity injection from Foresight Group with a £3 million R&D grant from Scottish Enterprise, aimed at accelerating its advanced diagnostic platform’s international expansion and operational growth 12.
Founded in 2012, Regenerus has steadily established itself as a vital clinical partner, offering over 150 tests complemented by digital tools, educational resources, and clinical support. Their innovative data analysis platform integrates biomarkers, DNA insights, and symptom tracking to deliver a comprehensive health overview. This empowers healthcare practitioners to provide faster, evidence-based care, aligning with the broader shift toward preventative medicine and longevity-focused healthcare strategies that are reshaping the sector today 3.
Prof Ben Thomson, Chairman and Co-founder of Regenerus, underscores the transformative potential of this investment: “With Foresight as an institutional equity partner and support from Scottish Enterprise, we have the resources to scale decisively and drive the industry forward. Advanced diagnostic testing is critical to easing the pressure on secondary care by enabling earlier detection and better clinical insights.” This aligns with the growing emphasis on early intervention and personalised health strategies, which are becoming central to modern healthcare delivery.
A standout feature of Regenerus’s platform is ‘Find A Practitioner,’ a tool that connects patients with qualified professionals capable of interpreting complex health results and translating them into actionable insights. This innovation bridges the gap between functional testing and personalised care, marking a crucial step in preventative healthcare and patient empowerment.
Katie Gilmartin, Investment Manager at Foresight Group, highlights the company’s promising trajectory: “Regenerus is improving access and connectivity in the functional health diagnostics market through scientific rigour and technological innovation. Their clear vision puts healthcare professionals at the heart of the model, focusing on improving patient outcomes.”
As healthcare demands intensify, Regenerus Laboratories is poised to equip practitioners with the tools necessary for early detection and effective intervention. This investment not only accelerates their growth but also heralds a new era of personalised, data-driven diagnostics that could redefine patient care across the UK and beyond.
For laboratory managers, scientists, and healthcare professionals, these advancements signal an exciting opportunity to integrate cutting-edge diagnostics into practice, enhancing accuracy and patient outcomes. The future of healthcare is evolving—are you ready to be part of it?
